# Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis

> **NCT03167957** · PHASE2 · WITHDRAWN · sponsor: **Matinas BioPharma Nanotechnologies, Inc.**

## Conditions studied

- Vulvovaginal Candidiases
- Yeast Infection
- Vulvovaginitis
- Yeast Infection Vaginal
- Candidiasis, Vulvovaginal

## Interventions

- **DRUG:** Oral Encochleated Amphotericin B (CAMB)
- **DRUG:** Oral Encochleated Amphotericin B (CAMB)

## Key facts

- **NCT ID:** NCT03167957
- **Lead sponsor:** Matinas BioPharma Nanotechnologies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-12
- **Primary completion:** 2020-12
- **Final completion:** 2020-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No longer target indication
- **Last updated:** 2019-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03167957

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03167957, "Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03167957. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*